[PDF][PDF] 23 价肺炎球菌多糖疫苗在慢性阻塞性肺疾病患者中的免疫原性和效果
李燕， 张琳， 安志杰， 王华庆 - 中国公共卫生, 2021 - zgggws.com
肺炎球菌是导致慢性阻塞性肺疾病(COPD) 患者感染性急性加重的主要病原体之一.
世界卫生组织等权威机构均推荐COPD 患者接种肺炎球菌疫苗, 但肺炎球菌疫苗对COPD …
世界卫生组织等权威机构均推荐COPD 患者接种肺炎球菌疫苗, 但肺炎球菌疫苗对COPD …
Immunogenicity and effectiveness of 23-valent pneumococcal polysac-charide vaccine in patients with chronic obstructive pulmonary disease: a review
Y LI, L ZHANG, Z AN - 中国公共卫生, 2021 - zgggws.com
Pneumococcus is one of main pathogens leading to infectious acute exacerbation in
patients with chronic obstructive pulmonary disease (COPD). The World Health Organization …
patients with chronic obstructive pulmonary disease (COPD). The World Health Organization …
[HTML][HTML] Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease—Hebei Province, China …
Y Li, Y Ma, Z An, C Yue, Y Wang, L Wang, Y Liu… - China CDC …, 2021 - ncbi.nlm.nih.gov
The global burden of chronic obstructive pulmonary disease (COPD) is serious.
Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23 …
Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23 …
[HTML][HTML] 23 价肺炎疫苗联合流感疫苗接种对慢性阻塞性肺疾病影响的Meta 分析
李钰婵， 戚萌， 梁楠， 杨淑梅， 兀威… - Advances in Clinical …, 2022 - hanspub.org
目的: 比较23 价肺炎球菌多糖疫苗, 流感疫苗联合接种和常规治疗对慢性阻塞性肺疾病(Chronic
Obstructive Pulmonary Disease COPD) 患者的临床防治效果. 方法: 检索时间从各数据库建库 …
Obstructive Pulmonary Disease COPD) 患者的临床防治效果. 方法: 检索时间从各数据库建库 …
[HTML][HTML] 慢性阻塞性肺疾病患者流感疫苗和23 价肺炎球菌多糖疫苗接种研究进展
随海田， 郭昱， 杨中楠， 苏锦锋， 舒祥， 张杨… - 中华流行病学 …, 2022 - html.rhhz.net
近年来国内外慢性阻塞性肺疾病(COPD) 患者流感疫苗和23 价肺炎球菌多糖疫苗(PPV23)
接种有效性的相关研究发现, 接种流感疫苗和PPV23 可显著降低COPD 患者的流感和肺炎感染 …
接种有效性的相关研究发现, 接种流感疫苗和PPV23 可显著降低COPD 患者的流感和肺炎感染 …
Progress in research of influenza vaccine and 23 valent pneumococcal polysaccharide vaccine immunization in patients with chronic obstructive pulmonary disease
HT Sui, Y Guo, ZN Yang, JF Su, X Shu… - Zhonghua liu Xing …, 2022 - europepmc.org
A comprehensive review of the research of the effectiveness of influenza vaccine and 23
valent pneumococcal polysaccharide vaccine (PPV23) in patients with chronic obstructive …
valent pneumococcal polysaccharide vaccine (PPV23) in patients with chronic obstructive …
老年肺炎球菌多糖疫苗免疫反应和保护效果研究进展
许玉洋， 刘艳， 安志杰 - 中国公共卫生, 2021 - zgggws.com
肺炎链球菌是引起婴幼儿和老年人发病和死亡的重要病因, 肺炎球菌性疾病是全球较为严重的
公共卫生问题之一, 肺炎球菌疫苗是预防肺炎链球菌感染的有效手段, 23 价肺炎球菌多糖疫苗 …
公共卫生问题之一, 肺炎球菌疫苗是预防肺炎链球菌感染的有效手段, 23 价肺炎球菌多糖疫苗 …
Effectiveness of 23-valent pneumococcal polysaccharide vaccine on adult pneumococcal disease
MC Li, ZJ Shao - Zhonghua yu Fang yi xue za zhi [Chinese Journal …, 2020 - europepmc.org
Streptococcus pneumoniae (Spn) will cause various pneumococcal diseases when host has
a weak immune system. The World Health Organization ranks it as one of the 12 key …
a weak immune system. The World Health Organization ranks it as one of the 12 key …
Progress on the effectiveness of the pneumococcal vaccination in patients with chronic obstructive pulmonary disease
YX Wu, J Zhang - Zhonghua jie he he hu xi za zhi= Zhonghua Jiehe …, 2022 - europepmc.org
Streptococcus pneumonia is an important pathogen leading to the acute exacerbation of
chronic obstructive pulmonary disease (COPD) or COPD with pneumonia. Pneumococcal …
chronic obstructive pulmonary disease (COPD) or COPD with pneumonia. Pneumococcal …
Post-marketing immunogenicity and safety of domestic 23-valent pneumococcal polysaccharide vaccine: a multicenter study
M ZHANG, R ZHANG, X YE, J ZHAO… - Chinese Journal of …, 2022 - pesquisa.bvsalud.org
Objective: To evaluate the post-marketing safety and immunogenicity of a 23-valent
pneumococcal polysaccharide vaccine (PPV23). Methods: From September 2020 to June …
pneumococcal polysaccharide vaccine (PPV23). Methods: From September 2020 to June …